Sciety

Sciety AB is a venture capital firm based in Stockholm, Sweden, specializing in seed and early-stage investments in life sciences companies. It focuses exclusively on the Nordic region, particularly in sectors such as biotechnology, pharmaceuticals, medical technology, and health tech. Sciety combines expertise in life sciences and finance to identify promising startups, investing its own funds in those that meet its selection criteria. Additionally, it facilitates a network for co-investment alongside other venture capital firms, family offices, and business angels, ensuring that investments can range from 1 to 10 million euros. Regulated by the Swedish financial supervisory authority, Sciety is also a member of key industry associations, reflecting its commitment to supporting innovations within the life sciences sector.

Andreas Lindblom

Founding Partner and CEO

Past deals in Sweden

Capitainer

Series A in 2023
Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

PharmNovo

Venture Round in 2022
PharmNovo AB develops therapeutic drugs for the treatment of neuro disease. The company focuses on the clinical development of hyper excitability disorders, such as chronic pain using neuroscience and translational medicine. The company provides PN6047, which helps to reduce chronic pain and combat other hypersensitivity. PharmNovo AB was founded in 2008 and is based in Lund, Sweden.

Encare

Series A in 2022
Encare AB, founded in 2009 and based in Stockholm, Sweden, specializes in web-based software solutions designed to enhance surgical care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company offers a comprehensive suite of tools, including an ERAS protocol for perioperative care, an audit system for surgeries, an implementation tool, and a system for comparing outcomes. Encare's interactive platform allows surgical teams to collect and analyze critical performance data, providing immediate feedback that fosters improvements in efficiency and quality of care. The software has been successfully deployed in over 120 hospitals across multiple countries, facilitating the training of healthcare professionals and promoting evidence-based best practices in perioperative management. Encare holds the rights to commercialize surgical protocols developed by the ERAS Society, which aims to establish standardized guidelines for enhanced recovery in surgical patients.

Capitainer

Series B in 2022
Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

Synartro

Series A in 2021
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

SAGA Diagnostics

Series A in 2021
SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.

Capitainer

Series A in 2020
Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

Synartro

Series A in 2020
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

PharmNovo

Series A in 2020
PharmNovo AB develops therapeutic drugs for the treatment of neuro disease. The company focuses on the clinical development of hyper excitability disorders, such as chronic pain using neuroscience and translational medicine. The company provides PN6047, which helps to reduce chronic pain and combat other hypersensitivity. PharmNovo AB was founded in 2008 and is based in Lund, Sweden.

Synartro

Seed Round in 2020
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

Empe Diagnostics

Series A in 2020
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

Cavis Technologies

Seed Round in 2020
Cavis Technologies is an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.

Elypta

Seed Round in 2020
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.

Predicare

Seed Round in 2019
Predicare AB is a company based in Gothenburg, Sweden, that specializes in designing and developing decision support system solutions for the healthcare sector. Its primary product, the RETTS system, enhances emergency triage and treatment by measuring vital parameters during initial examinations and collecting structured medical histories related to patients' symptoms and reasons for seeking care. Founded in 2010, Predicare focuses on providing efficient support for patients, families, medical staff, and healthcare providers to improve decision-making processes in medical settings.

Empe Diagnostics

Seed Round in 2019
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

Single Technologies

Seed Round in 2019
SINGLE TECHNOLOGIES AB develops single molecule sensitive 3D imaging system for research, drug discovery, and diagnostics. The product can be used to digitize the samples. SINGLE TECHNOLOGIES AB was founded in 2012 and is based in Stockholm, Sweden.

Athera Biotechnologies

Venture Round in 2019
Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit.

Likvor

Seed Round in 2019
Likvor AB, a medical device company, develops a system for neurological investigations. The company provides CELDA System for assessment of cerebrospinal fluid dynamics. Its CELDA System includes various parts, such as instrument, software, tool set, and a bed for the investigation; and available in English, Swedish, French, German, Finish, Danish, Norwegian, and Dutch languages. The company was founded in 2007 and is based in Umea, Sweden.

Lipigon Pharmaceuticals

Seed Round in 2019
Lipigon Pharmaceuticals is specialized in fat metabolism and develops new blood lipids. Lipigon is currently focusing on developing drugs directed against the enzyme lipoprotein lipase (LPL). People with low activity at LPL have a higher incidence of elevated blood fats and also related disorders such as insulin resistance and metabolic syndrome. Thanks to Lipigon's expertise in this area, AstraZeneca has chosen to enter into a cooperation agreement with the Company to develop LPL-based pharmaceuticals. Lipigon can receive up to $ 110 million in compensation at achieved milestones related to development and sales.

CARTANA

Seed Round in 2018
Cartana AB operates as a biotechnology company which maps gene expression in brain tissue via In Situ Sequencing. The company’s products include NeuroKit: Brain Cell Mapping which identifies more than 100 genes in a single tissue section and sequencing services which perform sample preparation at laboratory and send the samples to CARTANA. Cartana AB was founded in 2017 and is headquartered in Solna, Sweden. As of August 21, 2020, Cartana AB operates as a subsidiary of 10x Genomics, Inc.

Empe Diagnostics

Funding Round in 2018
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

PictureMyLife

Seed Round in 2018
The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

Medpro Clinic Group

Series A in 2017
Medpro Clinic Group is a healthcare business that operates six innovative care centers and provides care with a personal service and high standards. Medpro Clinic's operations are run by a dedicated staff who are passionate about care with high quality and preserved integrity. Medpro Clinic Group is headquartered in Sweden.

Liv Diagnostics

Series A in 2017
Liv Diagnostics AB develops a diagnostic tool to analyze tumor cells in order to determine the risk of metastasis. The company was founded in 2016 and is based in Molndal, Sweden.Liv Diagnostics AB operates as a subsidiary of AstraZeneca BioVenture Hub AB. As of December 11, 2019, Liv Diagnostics AB operates as a subsidiary of Cline Scientific AB (publ).

Raytelligence

Seed Round in 2017
Raytelligence AB (publ) provides microwave sensors for healthcare and industrial markets in Sweden. Its products include RayVS1, a radar sensor for vital sign monitoring and high performance measurement for measuring position, movement, and respiration of humans or animals in proximity of the sensor. The company offers solution for monitoring elderly in homes. Raytelligence AB (publ) is based in Halmstad, Sweden. Raytelligence AB (publ) is a subsidiary of Swedish Adrenaline AB.

1928 Diagnostics

Seed Round in 2017
1928 Diagnostics is a digital health company, crunching DNA data in the cloud, to enable healthcare providers fight antibiotic resistance. Our software service provide revolutionary outbreak tracing and diagnostics for full infection control at any hospital.

MedFilm

Seed Round in 2017
MedFilm specializes in enhancing communication within the healthcare sector by providing 3D animated films that convey information about surgical interventions to patients. The company's platform offers these animated films in over a dozen languages, aiming to improve patient understanding, confidence, and participation in their healthcare journey. These films are utilized in hospitals across Scandinavia, presented on waiting room screens and through film tablets that offer information upon patient admission and awakening. By making complex medical information accessible and engaging, MedFilm supports healthcare providers in delivering effective patient education and care.

PictureMyLife

Seed Round in 2016
The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

Learning to Sleep

Seed Round in 2016
Learning to Sleep AB is a digital care provider based in Malmo, Sweden, specializing in evidence-based improvement programs for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary products: "Improve my Sleep," aimed at those with minor sleep issues requiring slight adjustments, and "Learning to Sleep," designed for individuals with more severe conditions to help restore their sleep memory. These clinically proven programs are accessible through web and mobile platforms, allowing users to engage with the treatment conveniently. Learning to Sleep has successfully assisted over 40,000 individuals, fostering a strong connection between patients and their psychologists through its unique business model.

Learning to Sleep

Venture Round in 2016
Learning to Sleep AB is a digital care provider based in Malmo, Sweden, specializing in evidence-based improvement programs for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary products: "Improve my Sleep," aimed at those with minor sleep issues requiring slight adjustments, and "Learning to Sleep," designed for individuals with more severe conditions to help restore their sleep memory. These clinically proven programs are accessible through web and mobile platforms, allowing users to engage with the treatment conveniently. Learning to Sleep has successfully assisted over 40,000 individuals, fostering a strong connection between patients and their psychologists through its unique business model.

Attana

Series A in 2016
Attana AB provides biologically related information to customers in developing pharmaceutical drugs primarily in Europe and Asia. The company offers analytical biosensor instruments for automated analysis of molecular interactions with cells and tissues; and contract research services. It serves academic institutions, biotech companies, and pharma companies. Attana AB was founded in 2002 and is headquartered in Stockholm, Sweden.